Prof. Jinsei Jung
Dept. of Otorhinolaryngology
Infectious disease, Hearing Loss
Hearing loss, Chronic Otitis Media, Antibiotics, Resistance
Current development stage
General list: TRL 4 Technology validated in lab
By eliminating pathogens and fine-tuning the immune response, the treatment and prevention of sensorineural hearing loss induced by pathogens can be expected. However, the mechanisms associated with this fine immunological modulation have not been disclosed until now. This technique confirms that threshold values for hearing response contribute to hearing recovery compared with control mice when peptide L is externally treated with Pseudomonas infected mice, which is related with anti-bacterial function of L peptide. Peptide L is a potential drug candidate for the treatment of sensorineural hearing loss as well as chronic otitis media.